Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Cash from Investing Activities (2025)

Drugs Made In America Acquisition filings provide 1 years of Cash from Investing Activities readings, the most recent being -$231.2 million for Q1 2025.

  • Quarterly Cash from Investing Activities changed N/A to -$231.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$231.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$231.2 million for FY2025, N/A changed from the prior year.
  • Cash from Investing Activities hit -$231.2 million in Q1 2025 for Drugs Made In America Acquisition.
  • Across five years, Cash from Investing Activities topped out at -$231.2 million in Q1 2025 and bottomed at -$231.2 million in Q1 2025.